American Multinational Corporation Johnson & Johnson Stock Underperforms

Johnson & Johnson shares shed 0.28% to $170.08 Tuesday, on what proved to be an all-around dismal trading session for the Stock market, with the S&P 500 Index SPX falling 0.21% to 4,188.13 and Dow Jones Industrial Average DJIA falling 0.24% to 34,312.46. This was the Stock third consecutive day of losses.

Johnson & Johnson closed $3.57 below its 52-week high ($173.65), which the company achieved on January 26th. The Stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Roche Holding AG Part. Cert. RHHVF rose 4.23% to $350.00, Merck & Co. Inc. MRK fell 1.94% to $77.50, and Pfizer Inc. PFE fell 1.21% to $39.33. Trading volume (7.3 M) eclipsed its 50-day average volume of 7.2 M.

Johnson & Johnson delivered another good quarter showing a 7.9% year-over-year increase in revenue, while the company’s Stock price has seen a 25% increase since the start of 2021. To determine if shares are currently undervalued, we took a look at the company’s fundamentals and projected its free cash flow over the next five years. We reached an estimated fair value of $196 per share based on specific growth and margin assumptions.

The pharmaceutical segment, which accounts for 55% of consolidated revenues, was the least impacted by the COVID-19 pandemic last year. This segment’s revenue increased by 8% during 2020. During Q1, revenue reached $12.2 billion, rising by 9.6%. The vaccine authorization did not significantly impact the company’s revenues since it was approved in late February.